Observational studyThe lancet. HIV2017

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.

Nicholas I Paton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.